ABSTRACT
INTRODUCTION
Progesterone, often called the pregnancy hormone, is a 21-carbon steroid hormone associated with pregnancy. A pregnant woman has approximately 10 times more progesterone in her blood, as compared with non-pregnant women, and its levels increase steadily during the entire pregnancy. Progesterone is produced by the corpus luteum in the ovaries and later on during the pregnancy, its level is maintained by the placenta. It is an essential hormone for the establishment and maintenance of pregnancy by inducing secretary changes in the lining of the uterus, which are important for implantation of the fertilized ovum (4).
Progesterone is also widely used in in-vitro fertilization (IVF) therapies (20) . In IVF, the follicles are aspirated with a needle, removing many of the cells which would otherwise form the corpus luteum. It is adequate progesterone that prevents the shedding of uterine lining and if its level is not enough at the time when embryos have been put back can lead to failure of IVF cycle. Thus, since the early days of IVF, progesterone supplementation has been used to make up for the deficit
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created by removal of these cells (14) . In this context, progesterone is usually prescribed starting at the latter part of the menstrual cycle and continuing on to 8 th -10 th weeks of the pregnancy.
Babies born through IVF are up to 4% more likely to suffer from birth defects that range from relatively minor problems like cleft palate to severe ones such as spina bifida (6) . The cause of the defects is not certain; however, possible explanations include the methodology of the procedure itself, how the egg, sperm or embryo are manipulated, or the medications that are given to induce ovulation or to sustain pregnancy (6) .
Around the world, there are hundreds of thousands of pregnancies affected each year by an NTD, with some fetal demise through spontaneous or induced losses. Seven percent of infant deaths from birth defects are a result of NTDs. Based on animal studies, epidemiologic studies and intervention trials, maternal folic acid (vitamin B9) is known to be protective for neural tube defects (NTD), primarily spina bifida and anencephalus (8) .
The present study was designed to describe the role of folic acid in the prevention of neural tube development defects caused by high dose progesterone. The hypothesis under consideration was that folic acid prevents the neural tube defect caused by high dose progesterone.
MATERIAL and METHODS
The study design of this project was experimental. The study protocol was reviewed and approved by the Institutional Ethics Review Committee of Army Medical College, Rawalpindi. Chick embryos were exposed to N/S, HDP, and HDP with FA supplement, and compared with controls to see the effect of HDP on NTDs and also to analyse the role of FA in prevention of NTDs caused by HDP. The project was carried out at the Poultry Research Institute, Rawalpindi. The study was done on four main groups. 
Control Group

Description of chick embryos
Fertile, specific pathogen free eggs of Fyoumi species of chick were selected and obtained from Poultry Research Institute Punjab, Rawalpindi at zero hour of incubation. The eggs were incubated at 37.5º C and 75% relative humidity until the embryos reached stage eight of development according to Hamburger and Hamilton (7) . At this stage the eggs were labelled and divided into four groups consisting of 15 eggs per group. These groups were: 
Dosage of progesterone
The normal progesterone level that a chick embryo is exposed to is found to be 0.823 ± 0.035 nanogram/ml (18) . The calculated dose of progesterone, 157 nanograms, (Water Soluble Progesterone, Sigma -Aldrich Comp. code: P7556, St. Louis, Missouri, USA) was diluted in 0.1 ml of physiological saline (0.9% NaCl) for G3. G4 was injected with progesterone 157 nanograms diluted in 0.1 ml of physiological saline (0.9% NaC l) along with supplement of 5 micrograms/embryo folic acid (13) .
Method of injection
At stage eight of development, (26 to 29 hrs) the eggs from G2, G3, and G4 were washed with 70% alcohol and properly labelled on the outer shell. A hole was made on the blunt pole of the eggs with a sharp and thick needle under laminar flow. Using a sterile 28-gauge needle and a tuberculin syringe, 0.1 ml of the fluid was injected from the blunt end under the embryonic disc. The holes were sealed with paraffin. The eggs were then being placed again in the hatchery.
Embryo collection
The eggs were opened at 48 hours of incubation. The eggs were cracked open and the outer shells were chipped out to create a large opening to see the embryo. The viability of the embryos was assessed by the heartbeat. The embryos were transferred to a Petri dish by careful dissection along the allantoic stalk and other embryonic structures. All the embryos were fixed with Carnoy's fluid and were stained with HCl-carmine and examined under stereomicroscope to assess any gross developmental abnormalities. Then, embryos which were passed Hamburger Hamilton stage 12 were embedded into paraffin and seven microns thick paraffin sections were cut for light microscopic examination.
RESULTS
Quantitative Observations
After 48 hours of incubation when embryos were examined directly under dissecting microscope, and as whole mount and transverse section under light microscope, it was observed that in controlled groups G1 and G2, the neural tube was closed in all live embryos (Figure 1, 2) . However, 9/12 (75%) of the live embryos in G3 (Figure 3, 4 ) and 7/12 (58.3%) of the live embryos in G4 ( Figure 5, 6 ) had an open neural tube (Table I ). There was defect in the closure of neural tube mostly in the region of lumbosacral region (Figure 3, 5 ).
Qualitative Observations
Treatment of embryos with HDP resulted in a high percentage of embryos exhibiting non-closure-type neural tube defect.
Examination of defective regions of the embryos directly under dissecting microscope and as whole mount and transverse section under light microscope revealed that the neural folds usually elevated normally, but convergence often failed to occur (Figure 3, 6 ). In many of the embryos with neural tube defects, the elevated neural folds actually diverged, flaring laterally (Figure 4, 5) . The formation of neural tube defects in embryos treated with HDP were principally due to a failure of the elevated neural folds to converge toward the dorsal midline. Fusion occasionally failed to occur at various levels along the length of the spinal cord, but much more frequently fusion was inhibited only in the area of the posterior neuropore (Figure 3, 5) .
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DISCUSSION
The major finding of this study is that in chick embryos exposed to high dose progesterone, supplementation with folic acid reduces, but does not obviate the incidence of neural tube defects.
High dose extraneous progesterone is a known teratogen in certain animal models. In rabbit embryos, when progesterone is introduced at the appropriate time of embryonic development, neural tube defects result frequently (1). Mice and rats do not show such defects. In chick embryos, exposure to high dose, natural progesterone has been shown to cause neural tube defects (18) . In human embryos, use of natural progesterone is practiced frequently in threatened abortion, luteal phase defect and as part of in-vitro fertilization (IVF) therapy. The use is primarily intended to supplement the endogenous production of progesterone by the corpus luteum, and later the placenta, during pregnancy. IVF and Intra cytoplasmic sperm injection (ICSI) is the clinical context in which natural, exogenous progesterone is administered during the period of organogenesis of the embryo. Thus, the findings of the present study are particularly relevant to IVF and ICSI, which is being performed with increasing popularity all around the world. Theoretically, the dosage of exogenous progesterone administered during in-vitro fertilization should be small, as it is intended to make up for the iatrogenically induced deficiency of endogenous progesterone caused by the use of GnRH agonists or antagonists during the procedure of IVF. International guidelines state a maximum daily dose of 600 mg progesterone as vaginal gel or pessaries, and thus reduce the binding, and thus the agonistic effects of high dose progesterone on GABA-A receptors. It would be pertinent to test this hypothesis in future experimental studies, and to seek a dose-response relationship between folic acid and progesterone supplementation on GABAreceptors and neural tube development, that would be of clinical use to women undergoing IVF treatment. Another study done by Elisa et al. show that progesterone, a sterol produced by the placenta, inhibits both FA uptake and efflux in BeWo cells and primary cultured human trophoblasts (11) , in view of this study it can be considered that HDP might be responsible for NTDS by acting on trophoblast, inhibiting folic acid uptake and then producing its deficiency. Further studies are needed to prove this effect and to study whether these NTD could be prevented by increasing the dose of folic acid.
There are multiple unanswered questions in relation to this study that can be addressed in future research work. It is not conclusively known whether the increased risk of neural tube defects in babies born through IVF is related to progesterone. Progesterone dosage regimens in IVF are non-standardized and multiple additional factors such as absorption and metabolism of various dosing forms used in IVF need to be evaluated in detail. Large, follow-up studies on babies born through IVF would be able to settle this question in future research.
Further research is required to highlight the interaction of progesterone and folic acid on embryonic neural tissue and to explore whether a dose-response mechanism exists. Only then, definite recommendations can be made on the need for reduction of use of progesterone, or preferential use of a specific preparation or route, or supplementation that would decrease the risk for neural tube defects caused by progesterone in babies born through IVF.
In conclusion, the present study found that exposure to high dose progesterone greatly increases the incidence of neural tube defects in chick embryos. Concurrent supplementation with folic acid decreased the incidence of the defects, but did not obviate them. Further research is required to explore the relationship between natural progesterone and neural tube defects in humans.
or 100 mg intramuscular (20 ) and the average serum levels of progesterone achieved at this dose would be around 50-60 ng/ml (19) however, anecdotal evidence from Pakistani IVF specialists suggests that in clinical practice, the doses have been known to go up to 1600 mg daily (in case of multiple pregnancies), and plasma levels reaching over 250 ng/mlseven to thirty times the normal range of 9-45 ng/ml in first trimester (personal communication with IVF specialists in Pakistan). Serum levels this high correspond to the 20 times physiological levels of progesterone that was introduced in the present experiment.
Although a large number of studies have failed to show progesterone as a human teratogen (10, 12, 21) . It would be pertinent to note that almost all of the major studies performed to explore the link of exogenous progesterone with birth defects were carried out in the 1970s and 1980s, when in-vitro fertilization was not as common as it is nowbeing the mechanism of conception in almost 1% of all live births in developed countries. All of the studies were casecontrol, and suffer from biases relating to recall of information relating to the initial part of the pregnancy, when actual questioning occurred almost 9 months later, after the delivery of the baby. None of the studies explored a dose-response relationship with high dose progesterone administered in the period of organogenesis. Finally, IVF, the only large scale use of natural progesterone in the teratogenically relevant period of pregnancy, has been shown to increases the risk of neural tube defects (9) . Whether it is due to the use of exogenous progesterone or not is not known, but, the discussion on the role of progesterone in occurrence of neural tube defects during IVF is far from conclusive.
Folic acid supplementation during pregnancy is routine, considering its proven benefits on reduction of neural tube defects in the fetus (2) . Although folate supplementation has reduced the incidence of neural tube defects by 70% (5), as the present study found, it will reduce by not completely abolish neural tube defects caused due to exposure to exogenous progesterone. Modification of activity on GABA-A receptor in neural embryonal neural tissue is the key to understanding the effects of progesterone and the decrease in frequency of progesterone induced neural tube defects by folic acid, as noted in the present study. GABA-A receptor agonists increase the frequency of neural tube defects, especially spina bifida (3); the anti-epileptic drug Valproic acid, which is notorious for its teratogenic effects, and has important effects on the GABA-A receptor, may act through this pathway (3, 16) . Progesterone acts as an agonist at GABA-A receptors (16) . Folic acid itself has been shown to reduce GABAergic action at GABA-A receptors by its interaction with this receptor complex (22) . In reduction of neural tube defects induced by high dose progesterone, the role of folic acid is probably different from its actions in prevention of neural tube defects not induced by high dose progesterone, which are postulated to be due to its effects on homocystiene and methionine metabolism(15). In view of the aforementioned data, it is hypothesized that folic acid may act as an antagonist at GABA-A receptor complex,
